<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436695</url>
  </required_header>
  <id_info>
    <org_study_id>EPC - 01</org_study_id>
    <nct_id>NCT01436695</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers</brief_title>
  <official_title>Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epicall LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epicall LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epilepsy is a syndrome of episodic brain dysfunction characterized by recurrent seemingly&#xD;
      unpredictable spontaneous seizures. The occurrence of the seizure in patients without any&#xD;
      forewarning is the most debilitating aspect of the disease.&#xD;
&#xD;
      The Epicall system is intended for early detection of seizure related life threatening events&#xD;
      by monitoring per-seizures biomarkers. The system is based on a sticker placed on the side of&#xD;
      the face. The external sticker incorporates EOG (electrooculograph electrode) and PPG&#xD;
      (photoplethysmograph electrode) sensors for continuous monitoring of:&#xD;
&#xD;
        1. Heart Rate (base line, increase, decrease, asystole).&#xD;
&#xD;
        2. Extra ocular eye movement (blinking, eye deviation, roving eye movements).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lack of adverse events</measure>
    <time_frame>1-2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epicall feasibility for monitoring pre-seizure biomarkers</measure>
    <time_frame>1-2 weeks</time_frame>
    <description>Feasibility of using the Epicall for monitoring pre-seizure biomarkers will be established by the correlation between Epicall and ECG heart rate measurements.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Seizure</condition>
  <arm_group>
    <arm_group_label>Epicall group</arm_group_label>
    <description>patients will be connected to Epicall sensor</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Epicall</intervention_name>
    <description>The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.</description>
    <arm_group_label>Epicall group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients who diagnosed with epilepsy and meet all of the eligibility criteria&#xD;
        will be recruited for the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children age 1 year -18 years old.&#xD;
&#xD;
          -  Hospitalized patient who is diagnosed with epilepsy.&#xD;
&#xD;
          -  Patient's parents/care giver able to comprehend and give informed consent for&#xD;
             participation in this study.&#xD;
&#xD;
          -  Patient's parents/care giver must commit to both screening and monitoring visits.&#xD;
&#xD;
          -  Patient's parents/care giver must sign the Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with any infection / abscess / bleeding / blister / crack / edema / fissure /&#xD;
             ulcer / pain in monitoring electrode area&#xD;
&#xD;
          -  General weakness.&#xD;
&#xD;
          -  Patient's parents/care giver objects to the study protocol.&#xD;
&#xD;
          -  Concurrent participation in any other clinical study.&#xD;
&#xD;
          -  Physician objection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eli Heyman, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asaf-Harofeh Medical Center, Zrifin Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna Levy, Dr</last_name>
    <phone>+972-4-638-8837</phone>
    <email>hanna@qsitemed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asaf Harofeh Medical Center</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Hanna Levy, Dr</last_name>
      <phone>+972-4638-8837</phone>
      <email>hanna@qsitemed.com</email>
    </contact>
    <investigator>
      <last_name>Eli Heyman, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>September 17, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2011</study_first_posted>
  <last_update_submitted>September 19, 2011</last_update_submitted>
  <last_update_submitted_qc>September 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seizure early detection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

